Raltegravir in the management of HIV-infected patients

References

• AndersonMSWenningLAMoreauA2007Effect of raltegravir (RAL) on the pharmacokinetics (PK) of oral contraceptives [abstract]47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)17–20 September 2007Chicago, IL, USA abstract A-1425. 2007
   Google Scholar
• CooperDAGatellJRockstrohJ2007Results of BENCHMRK-1, a Phase III study evaluating the efficacy and safety of MK-0518, a Novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus [abstract]14th Conf Retro Opportun InfectLos Angeles abstract 105aLB
   Google Scholar
• CooperDASteigbigelRTGatellJM2008Subgroup and resistance analyses of raltegravir for resistant HIV-1 infectionN Engl J Med3593556518650513
   PubMed Web of Science ®Google Scholar
• CraigieR2001HIV integrase, a brief overview from chemistry to therapeuticsJ Biol Chem276232131611346660
   PubMed Web of Science ®Google Scholar
• DeJesusECohenCElionR2007First report of raltegravir (RAL, MK-0518) use after virologic rebound on elvitegravir (EVT, GS 9137) [abstract]4th IAS Conference on HIV Pathogenesis, Treatment and PreventionSydney, Australia22–25, July 2007 Abstract TUPEB0322007
   Google Scholar
• EmbreyMWWaiJSFunkTW2005A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluoro-benzylamide inhibitors of HIV-1 integrase and viral replication in cellsBioorg Med Chem Lett154550416102965
   PubMed Web of Science ®Google Scholar
• EspesethASFelockPWolfeA2000HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integraseProc Natl Acad Sci U S A9711244911016953
   PubMed Web of Science ®Google Scholar
• GoethalsOClaytonRWagemansE2008Resistance mutations in HIV-1 integrase selected with raltegravir or elvitegravir confer reduced susceptibility to a diverse panel of integrase inhibitors [abstract]XVII International HIV Drug Resistance WorkshopJune 10–14, 2008Sitges Spain abstract no. 2008
   Google Scholar
• GrinsztejnBNguyenBYKatlamaC2007Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II ran-domised controlled trialLancet3691261917434401
   PubMed Web of Science ®Google Scholar
• HarrisMLarsenGMontanerJS2008aExacerbation of depression associated with starting raltegravir: a report of four casesAIDS221890218753871
   PubMed Web of Science ®Google Scholar
• HarrisMLarsenGMontanerJS2008bOutcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimenAids221224618525270
   PubMed Web of Science ®Google Scholar
• HazudaDBlauCUFelockP1999Isolation and characterization of novel human immunodeficiency virus integrase inhibitors from fungal metabolitesAntivir Chem Chemother10637010335400
   PubMed Web of Science ®Google Scholar
• HazudaDMillerMDNguyenBY2007Resistance to the HIV-integrase inhibitor raltegravir: analysis of Protocol 005, a Phase 2 study in patients with triple-class resistant HIV-1 infection [abstract]Antivir Ther abstract no. 8[12]S10
   Google Scholar
• HazudaDJAnthonyNJGomezRP2004A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integraseProc Natl Acad Sci U S A10111233815277684
   PubMed Web of Science ®Google Scholar
• HazudaDJFelockPWitmerM2000Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cellsScience2876465010649997
   PubMed Web of Science ®Google Scholar
• IwamotoMKassahunKTroyerMD2008aLack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlationJ Clin Pharmacol482091418077730
   PubMed Web of Science ®Google Scholar
• IwamotoMWenningLALiouSY2006aRifampin (RIF) modestly reduces plasma levels of MK-0518 [abstract]8th international congress on drug therapy in HIV infectionGlasgow, United KingdomNovember 12–16, 2006 abstract P299
   Google Scholar
• IwamotoMWenningLAPetryAS2006bMinimal effect of ritonavir (RTV) and efavirenz (EFV) on the pharmacokinetics (PK) of MK-0518 [abstract]46th Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 27–30, 2006San Francisco, USA abstract A-373
   Google Scholar
• IwamotoMWenningLAPetryAS2008bSafety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjectsClin Pharmacol Ther832939917713476
   PubMed Web of Science ®Google Scholar
• KassahunKMcIntoshICuiD2007Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzymeDrug Metab Dispos3516576317591678
   PubMed Web of Science ®Google Scholar
• KassahunKMcIntoshIHreniukDAbsorption, metabolism and excretion of MK-0518, a potent HIV-1 integrase inhibitor, in healthy male volunteers [abstract]46th Interscience Conference on 1 Agents and ChemotherapySeptember 27–30, 2006San Francisco, USA abstract A-372
   Google Scholar
• LafeminaRLSchneiderCLRobbinsHL1992Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cellsJ Virol667414191433523
   PubMed Web of Science ®Google Scholar
• MaletIDelelisOValantinMA2008Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitroAntimicrob Agents Chemother521351818227187
   PubMed Web of Science ®Google Scholar
• MarkowitzMNguyenBYGotuzzoE2008Sustained antiretroviral efficacy of raltegravir as part of combination ART in treatment-naive HIV-1 infected patients: 96-week data [abstract]17th International AIDS ConferenceAugust 3–8, 2008Mexico City, Mexico Abstract TUAB0102
   Google Scholar
• MarkowitzMNguyenBYGotuzzoE2007Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled studyJ Acquir Immune Defic Syndr461253317721395
   PubMed Web of Science ®Google Scholar
• Merck and Co., W. S. N. O. UIsentress™ FDA Briefing DocumentFood And Drug Administration Homepage2007 www.fda.gov/ohmrs/dockets/ac/07/briefing/2007-4314b1-01-Merck.pdf
   Google Scholar
• Merck and Co., W. S. N. O. UIsentress™ Prescribing InformationUS Food and Drug Administration Homepage2008 www.fda.gov/cder/foi/label/2007/0221451b1.pdf
   Google Scholar
• MistryGWenningLPetryA2007Atazanavir modestly increases plasma leves of MK-0518 [abstract]4th IAS Conference on HIV Pathogenesis, Treatment and PreventionSydney, Australia22–25, July 2007 abstract 1985
   Google Scholar
• MurrayJMEmerySKelleherAD2007Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phaseAids2123152118090280
   PubMed Web of Science ®Google Scholar
• PaisGCZhangXMarchandC2002Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitorsJ Med Chem4531849412109903
   PubMed Web of Science ®Google Scholar
• RoquebertBDamondFCollinGon behalf of the French ANRS HIV- 2008HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvite-gravir in vitroJ Antimicrob Chemother10.1093/jac/dkn335
   Web of Science ®Google Scholar
• SedaghatARDinosoJBShenL2008Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycleProc Natl Acad Sci U S A1054832718362342
   PubMed Web of Science ®Google Scholar
• SteigbigelRKumarPEronJ2007Results of BENCHMRK-2, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus [abstract]14th Conf Retro Opportun InfectLos Angeles abstract 105bLB
   Google Scholar
• van BaelenKvan EygenVRondelezE2008Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibilityAids Epub ahead of print
   PubMed Web of Science ®Google Scholar
• WenningLAFriedmanEKostJT2006aLack of a significant drug interaction between MK-0518 and tenofovir disoproxil fumarate (TDF) [abstract]46th Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 27–30, 2006San Francisco, USA abstract A-375
   Google Scholar
• WenningLAHanleyHStoneJ2006bEffect of tipranavir + ritonavir (TPV + RTV) on pharmacokinetics of MK-0518 [abstract]46th Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 27–30, 2006San Francisco, USA abstract A-3742006b
   Google Scholar